1Meredith PA, Perloff D, Mancia G, et al. Blood pressure variability and its implications for anti hypertensive therapy. Blood Press,1995; 4(1) :5～11
2Waeber B,Eme P,Saxenhofer H,et al. Use of drugs with more than a twenty-four-hour duration of action. J Hypertens, 1994 ; 12(Suppl) : 567～571
3Palatini P,Penzo M,Racioppa,A,et al. Clinical relevance of night time blood pressure and daytime blood pressure variability. Arch Intern Med, 1992 ; 152(9) : 1855～1860
4Schlienger RG, Saxer M, Haefeli WE. Reversible ageusia associated with losartan. Lancet, 1996 ; 347 ( 8999 ) : 471～472
5Acker CG,Greenberg A. Anqioedema induced by the angiotensin Ⅱ blocker losartan. N Engl J Med, 1995; 333 (23) : 1572
6Anonymous. 1999 World Health Organzation-Intenational society of hypertension guidelines for the mangement of hypertension. J Hypertens, 1999; 17(2): 151～183
7Mackay JH, Arcnri KE, Goldberg AI, et al. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. Arch Intern Med, 1996; 156(3): 278～285
8Goldberg AI, Dunlay MC, Sweet CS, et al. Safety and tolerability of losartan potassium, an angiotensin Ⅱ receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol, 1995; 75(12): 793～795
9Critchley JAJH,Gilchrist N,Lked L,et al.A randomized, doublemasked comparison of the annthybertensive effect and safety of combination therapy with losartan and hydrochlorothizaide vs captopril and hydrochlorothizaide in elderly and younger patients[].Current Therapeutic Research.1996
10Hansson L,Zanclietti A,Carruthans SG,et al.Benefits of intensize blood pressure lowering and acerylsalicylic acid in hypertensive patients[].The Lancet.1998
